Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
Clinical Benefit
| Substantial |
The actual benefit of XELODA is substantial. |
Clinical Added Value
| no clinical added value |
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator. |
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
unsw4pVPnxn3PENR
